Sagimet (SGMT) Director George Kemble Sells 18,844 Shares

What Happened
George Kemble, a director of Sagimet Biosciences, sold 18,844 shares of SGMT in an open-market disposal on July 20, 2026. The weighted average sale price was $7.46 per share, for total proceeds of approximately $140,529. This was a sale (not a purchase or option exercise), which many insiders execute for routine reasons.

Key Details

• Transaction date: 2026-07-20; Form 4 filed 2026-07-22 (timely filing).
• Shares sold: 18,844; weighted average price reported: $7.46; total proceeds ≈ $140,529.
• Reported price range: shares were sold in multiple trades at prices from $7.17 to $7.97 (inclusive).
• Ownership after transaction: not disclosed in the provided filing excerpt.
• Footnotes of note:
  • F1: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Aug 21, 2025 (pre‑planned trades).
  • F2: Weighted average price reported; the filer will provide a per‑trade price breakdown upon request to the issuer, shareholders, or SEC staff.

Context
A 10b5-1 plan indicates the trades were pre-scheduled under a compliant trading arrangement and are generally considered routine (not necessarily a reflection of current views on the company). For retail investors, purchases tend to be more informative about insider sentiment than routine sales; this filing documents a planned disposal of shares.